| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes’ B and C colorectal carcinoma. A cost-effectiveness analysis
|
Norum, J.
|
|
|
8 |
1 |
p. 65-70
|
artikel
|
| 2 |
Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes B and Ccolorectal carcinoma. A cost-effectiveness analysis
|
J. Norum
|
|
1997
|
8 |
1 |
p. 65-70
6 p.
|
artikel
|
| 3 |
Application of long PCR to detect t(8;14)(q24;q32) translocations inchildhood Burkitts lymphoma and B-ALL
|
U. zur Stadt
|
|
1997
|
8 |
1 |
p. 31-35
5 p.
|
artikel
|
| 4 |
B-cell chronic lymphocytic leukemia: Recent progress in biology,diagnosis, and therapy
|
E. Montserrat
|
|
1997
|
8 |
1 |
p. 93-101
9 p.
|
artikel
|
| 5 |
Book review
|
Fogliata-Cozzi, A.
|
|
|
8 |
1 |
p. 6
|
artikel
|
| 6 |
Can the CD4+/CD8+ ratio predict the outcome of interferon-α therapy for renal cell carcinoma?
|
Hernberg, M.
|
|
|
8 |
1 |
p. 71-77
|
artikel
|
| 7 |
Can the CD4+/CD8+ ratio predict the outcome of interferon-α therapyfor renal cell carcinoma?
|
M. Hernberg
|
|
1997
|
8 |
1 |
p. 71-77
7 p.
|
artikel
|
| 8 |
Can we improve upon the International Index?
|
M. A. Shipp
|
|
1997
|
8 |
1 |
p. 43-47
5 p.
|
artikel
|
| 9 |
Car makers like tobacco producers?
|
|
|
|
8 |
1 |
p. 2
|
artikel
|
| 10 |
Comparison of gallium scan, computed tomography, and magnetic resonancein patients with mediastinal Hodgkins disease
|
L. Devizzi
|
|
1997
|
8 |
1 |
p. 53-56
4 p.
|
artikel
|
| 11 |
Contents of the next issue
|
|
|
|
8 |
1 |
p. vi
|
artikel
|
| 12 |
Copyright
|
|
|
|
8 |
1 |
p. iv
|
artikel
|
| 13 |
Dispute over breast cancer research funds in the US
|
|
|
|
8 |
1 |
p. 2-3
|
artikel
|
| 14 |
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer
|
Fetscher, S.
|
|
|
8 |
1 |
p. 49-56
|
artikel
|
| 15 |
Dose-intense therapy with etoposide, ifosfamide, cisplatin, andepirubicin (VIP-E) in 100 consecutive patients with limited- andextensive-disease small-cell lung cancer
|
S. Fetscher
|
|
1997
|
8 |
1 |
p. 49-56
8 p.
|
artikel
|
| 16 |
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer
|
Fetscher, S.
|
|
|
8 |
1 |
p. 57-64
|
artikel
|
| 17 |
Dose-intense therapy with etoposide, ifosfamide, cisplatin, andepirubicin (VIP-E) in 107 consecutive patients with limited- andextensive-stage non-small-cell lung cancer
|
S. Fetscher
|
|
1997
|
8 |
1 |
p. 57-64
8 p.
|
artikel
|
| 18 |
Dose intensity for bolus versus infusion chemotherapy administration: Review of the literature for 27 anti-neoplastic agents
|
Lokich, J.
|
|
|
8 |
1 |
p. 15-25
|
artikel
|
| 19 |
Dose intensity for bolus versus infusion chemotherapy administration:Review of the literature for 27 anti-neoplastic agents
|
J. Lokich
|
|
1997
|
8 |
1 |
p. 15-25
11 p.
|
artikel
|
| 20 |
Editorial board
|
|
|
|
8 |
1 |
p. v
|
artikel
|
| 21 |
Effects of phosphodiester and phosphorothioate antisenseoligodeoxynucleotides on cell lines which overexpress c-myc:Implications for the treatment of Burkitts lymphoma
|
S. A. Williams
|
|
1997
|
8 |
1 |
p. 25-30
6 p.
|
artikel
|
| 22 |
Eighty-one percent event-free survival in advanced Burkittslymphoma/leukemia: No differences in outcome between pediatric and adultpatients treated with the same intensive pediatric protocol
|
G. Todeschini
|
|
1997
|
8 |
1 |
p. 77-81
5 p.
|
artikel
|
| 23 |
European Cancer Experts recommendations for tobacco control
|
Boyle, P.
|
|
|
8 |
1 |
p. 9-13
|
artikel
|
| 24 |
European Cancer Experts recommendations for tobacco control
|
P. Boyle
|
|
1997
|
8 |
1 |
p. 9-13
5 p.
|
artikel
|
| 25 |
EU to support complementary medicine?
|
|
|
|
8 |
1 |
p. 3
|
artikel
|
| 26 |
Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 13–17, 1996, Ermatingen, Switzerland
|
Bunn, P.
|
|
|
8 |
1 |
p. 27-36
|
artikel
|
| 27 |
Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 1317, 1996,Ermatingen, Switzerland
|
P. Bunn
|
|
1997
|
8 |
1 |
p. 27-36
10 p.
|
artikel
|
| 28 |
Follicular lymphoma: Grounds for optimism
|
T. A. Lister
|
|
1997
|
8 |
1 |
p. 89-92
4 p.
|
artikel
|
| 29 |
For Germany, better late than never in biotech race
|
|
|
|
8 |
1 |
p. 1-2
|
artikel
|
| 30 |
Full speed ahead into our second period
|
Cavalli, F.
|
|
|
8 |
1 |
p. 7
|
artikel
|
| 31 |
Hepatitis B virus carriers in the treatment of malignant lymphoma:An epidemiological study in Japan
|
K. Kumagai
|
|
1997
|
8 |
1 |
p. 107-109
3 p.
|
artikel
|
| 32 |
Hodgkins disease: Complications of therapy and excess mortality
|
R. T. Hoppe
|
|
1997
|
8 |
1 |
p. 115-118
4 p.
|
artikel
|
| 33 |
Impact of high-dose salvage therapy (BEAM) on overall survival in youngerpatients with advanced large-cell lymphomas entered into BNLI trials
|
D. C. Linch
|
|
1997
|
8 |
1 |
p. 63-65
3 p.
|
artikel
|
| 34 |
Instructions to authors
|
|
|
|
8 |
1 |
p. 99-100
|
artikel
|
| 35 |
Interleukin-4 in the treatment of AIDS-related Kaposi’s sarcoma
|
Tulpule, A.
|
|
|
8 |
1 |
p. 79-83
|
artikel
|
| 36 |
Interleukin-4 in the treatment of AIDS-related Kaposis sarcoma
|
A. Tulpule
|
|
1997
|
8 |
1 |
p. 79-83
5 p.
|
artikel
|
| 37 |
In this Issue
|
|
|
|
8 |
1 |
p. vi
|
artikel
|
| 38 |
Is CHOP the standard of therapy for poor-prognosis large-celllymphoma?
|
G. P. Canellos
|
|
1997
|
8 |
1 |
p. 61-62
2 p.
|
artikel
|
| 39 |
Is the International Prognostic Index for aggressive lymphomas useful forlow-grade lymphoma patients? Applicability to stage IIIIVpatients
|
C. Foussard
|
|
1997
|
8 |
1 |
p. 49-52
4 p.
|
artikel
|
| 40 |
Late relapse of germ cell tumors after cisplatin-based chemotherapy
|
Gerl, A.
|
|
|
8 |
1 |
p. 41-47
|
artikel
|
| 41 |
Late relapse of germ cell tumors after cisplatin-based chemotherapy
|
A. Gerl
|
|
1997
|
8 |
1 |
p. 41-47
7 p.
|
artikel
|
| 42 |
Long-term pulmonary sequelae after treatment of childhood Hodgkinsdisease
|
G. Bossi
|
|
1997
|
8 |
1 |
p. 19-24
6 p.
|
artikel
|
| 43 |
Long-term survival advantage of MACOP-B over CHOP in intermediate-gradenon-Hodgkins lymphoma
|
M. Wolf
|
|
1997
|
8 |
1 |
p. 71-75
5 p.
|
artikel
|
| 44 |
New drugs in non-Hodgkins lymphoma
|
S. G. Arbuck
|
|
1997
|
8 |
1 |
p. 119-128
10 p.
|
artikel
|
| 45 |
One and a half decades of the Lugano International Conference onMalignant Lymphoma: Variations on a theme or true progress?
|
J. E. Ultmann
|
|
1997
|
8 |
1 |
p. 1-3
3 p.
|
artikel
|
| 46 |
Paclitaxel (Taxol®) for the treatment of lymphoma
|
A. Younes
|
|
1997
|
8 |
1 |
p. 129-131
3 p.
|
artikel
|
| 47 |
Patients with stage III/IV Hodgkins disease in partial remission afterMOPP/ABV chemotherapy have excellent prognosis after additional involved-fieldradiotherapy: Interim results from the ongoing EORTC-LCG and GPMC phase IIItrial
|
J. Raemaekers
|
|
1997
|
8 |
1 |
p. 111-114
4 p.
|
artikel
|
| 48 |
Perhaps not everyone knows that…
|
|
|
|
8 |
1 |
p. 4-5
|
artikel
|
| 49 |
Persistent improved results after adding vincristine and bleomycin to acyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stageIIIIV intermediate- and high-grade non-Hodgkins lymphoma
|
J. H. Meerwaldt
|
|
1997
|
8 |
1 |
p. 67-70
4 p.
|
artikel
|
| 50 |
Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity
|
Dimery, I.W.
|
|
|
8 |
1 |
p. 85-89
|
artikel
|
| 51 |
Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acidtoxicity
|
I. W. Dimery
|
|
1997
|
8 |
1 |
p. 85-89
5 p.
|
artikel
|
| 52 |
Primary lymphoma of the stomach: Three-year results of a prospectivemulticenter study
|
P. Koch
|
|
1997
|
8 |
1 |
p. 85-88
4 p.
|
artikel
|
| 53 |
Radioimmunotherapy strategies for non-Hodgkins lymphomas
|
M. C. Corcoran
|
|
1997
|
8 |
1 |
p. 133-138
6 p.
|
artikel
|
| 54 |
Rehearsal of the Nuremberg code
|
|
|
|
8 |
1 |
p. 3-4
|
artikel
|
| 55 |
Report of the Symposium on Cutaneous Lymphomas: Sixth InternationalConference on Malignant Lymphoma
|
E. S. Jaffe
|
|
1997
|
8 |
1 |
p. 83-84
2 p.
|
artikel
|
| 56 |
Residual mass following chemotherapy of seminoma
|
Horwich, A.
|
|
|
8 |
1 |
p. 37-40
|
artikel
|
| 57 |
Residual mass following chemotherapy of seminoma
|
A. Horwich
|
|
1997
|
8 |
1 |
p. 37-40
4 p.
|
artikel
|
| 58 |
Table of Contents
|
|
|
|
8 |
1 |
p. iii
|
artikel
|
| 59 |
The emerging role of immunotoxins in leukemia and lymphoma
|
U. Winkler
|
|
1997
|
8 |
1 |
p. 139-146
8 p.
|
artikel
|
| 60 |
The management of chronic myeloid leukaemia - a case history
|
Sureda, A.
|
|
|
8 |
1 |
p. 91-96
|
artikel
|
| 61 |
The Sixth Lugano Conference clinical papers: Many remainingquestions
|
R. Stupp
|
|
1997
|
8 |
1 |
p. 5-6
2 p.
|
artikel
|
| 62 |
The treatment of pediatric lymphomas: Paradigms to plagiarize?
|
I. T. Magrath
|
|
1997
|
8 |
1 |
p. 7-14
8 p.
|
artikel
|
| 63 |
This letter was referred to the authors, who respond as follows:
|
Lorigan, P.C.
|
|
|
8 |
1 |
p. 97
|
artikel
|
| 64 |
Title Page
|
|
|
|
8 |
1 |
p. ii
|
artikel
|
| 65 |
Treatment of childhood Hodgkins disease without radiotherapy
|
H. van den Berg
|
|
1997
|
8 |
1 |
p. 15-17
3 p.
|
artikel
|
| 66 |
Treatment of mantle-cell lymphomas with the VAD +/− chlorambucilregimen with or without subsequent high-dose therapy and peripheral bloodstem-cell transplantation
|
R. Gressin
|
|
1997
|
8 |
1 |
p. 103-106
4 p.
|
artikel
|
| 67 |
Tumor lysis syndrome, case report and review of the literature
|
Masera, G.
|
|
|
8 |
1 |
p. 97
|
artikel
|
| 68 |
Use of an anti-ALK antibody in the characterization of anaplasticlarge-cell lymphoma of childhood
|
R. E. Hutchison
|
|
1997
|
8 |
1 |
p. 37-42
6 p.
|
artikel
|
| 69 |
Whole-body positron emission tomography (PET) for diagnosis of residualmass in patients with lymphoma
|
M. de Wit
|
|
1997
|
8 |
1 |
p. 57-60
4 p.
|
artikel
|
Tijdschrift beschrijving